No Data
No Data
Nomura: Maintains a "buy" rating on Sinopharm, with a lowered target price of HKD 30.33.
Nomura released a research report stating that it lowered its target price for Sinopharm (01099) from HKD 32.39 to HKD 30.33 by 6.4% and maintained a "buy" investment rating. In the second quarter of 2023, the report expects that due to a high base and pessimistic environment, the performance of Sinopharm in the second quarter of 2024 may remain flat, and profits may decrease by 5.3% year-on-year. The report stated that adjusting the target price of Sinopharm means a potential increase of about 63%. The bank lowered its sales forecast for Sinopharm in fiscal 2024 and 2025 by 1.6% and 2.9%, respectively, and adjusted its profit forecast by 0.1% and -0.2% to consider the macro environment lower than expected.
Nomura: Maintains a "buy" rating on Sinopharm (01099), with a lowered target price of HKD 30.33.
Nomura predicts that Sinopharm (01099) may have a flat performance in the second quarter of 2024, with a possible year-on-year decrease of 5.3% in profits.
Sinopharm (01099.HK) faces shareholding of 1.3377 million shares by JPMorgan.
According to the latest equity disclosure information from the Stock Exchange, on July 19, 2024, Sinopharm Group (01099.HK) was reduced by JPMorgan Chase & Co. at an average price of HKD 18.8408 per share, with a total reduction of 1.3377 million shares involving approximately HKD 25.2025 million. After the reduction, JPMorgan Chase & Co.'s latest holding of outstanding shares is 93.9033 million, and the proportion of outstanding shares held has decreased from 7.09% to 6.99%.
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
Express News | Corrected-Sinopharm Tech Holdings FY23 (Not FY24) Revenue HKD 42.8 Million
Express News | Sinopharm Tech Holdings FY Revenue HKD 42.8 Million
No Data